Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs

December 22, 2025 — 08:19 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase inhibitor programs, including investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. Assembly Bio will receive a $35 million payment for Gilead's exercise of the combined HSV program option. Gilead will receive an exclusive license to ABI-5366 and ABI-1179 and will have the sole right and responsibility for further clinical development and commercialization of these programs.

Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs

Tags

Latest Articles